Postpartum Hemorrhage Clinical Trial
Official title:
Prophylactic Oxytocin Before Versus After Placental Delivery to Reduce Blood Loss in Vaginal Delivery
Randomized controlled study to assess the efficacy and safety of the timing of administration of prophylactic oxytocin via intramuscular route (before compared to after placental delivery) on blood loss in vaginal delivery.
Status | Recruiting |
Enrollment | 400 |
Est. completion date | September 2017 |
Est. primary completion date | August 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 35 Years |
Eligibility |
Inclusion Criteria: 1. Multiparous women (had previous one, up to four deliveries) 2. Term pregnancy (37 completed weeks at least). 3. Singleton viable cephalic pregnancy. 4. Vaginal delivery. Exclusion Criteria: 1. Primigravida.(first pregnancy) 2. Grand multiparous. (had previous 5 or more deliveries) 3. Maternal illness (involving pregnancy induced condition; PIH,GDM or chronic medical condition; hypertension, cardiac , renal problems) 4. Previous cesarean section, uterine surgery. 5. Patients with bleeding tendency. 6. Previous history of Ante-partum hemorrhage. 7. Previous history of postpartum hemorrhage. 8. Abnormal site of the placenta (detected by ultrasound) 9. Macrosomic baby (EFW more than 4000 gm estimated clinically or by ultrasound) 10. polyhydramnios.(detected by ultrasound) 11. Multiple gestation. 12. Chorioamnionitis. 13. Suspected fetal problem(anomaly, distress) 14. Instrumental delivery. 15. Multiple or deep vaginal tears that compromise the estimation of uterine blood loss. 16. Cesarean delivery |
Country | Name | City | State |
---|---|---|---|
Egypt | Ain Shams University Maternity Hospital | Cairo |
Lead Sponsor | Collaborator |
---|---|
Ain Shams Maternity Hospital |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | blood loss in vaginal delivery | blood loss in the third stage of labor (Up to 60 min after delivery of the baby) | ||
Secondary | primary postpartum hemorrhage | within 24 hours after delivery | ||
Secondary | changes in hemoglobin and hematocrit | before delivery and after 6 hours | ||
Secondary | retained placenta | more than 30 minutes after delivery | ||
Secondary | length of 3rd stage of labor | Up to 60 min from delivery of baby till delivery of placenta | ||
Secondary | manual removal of the placenta | if not separated after 30 minutes from delivery | ||
Secondary | blood pressure | to be measured before delivery after 15 minutes,1 hour,6 hours | ||
Secondary | maternal pain | during third stage of labor | ||
Secondary | maternal nausea and vomiting | during 3rd stage of labor | ||
Secondary | secondary postpartum hemorrhage | after 24 hours and before 6 weeks from delivery | ||
Secondary | surgical intervention to stop the bleeding | within 24 hours after delivery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03434444 -
In Vitro Optimization of Oxytocin-induced Myometrial Contractility by Propranolol
|
N/A | |
Terminated |
NCT01980173 -
Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care
|
N/A | |
Not yet recruiting |
NCT06033170 -
Celox™ PPH for Reaching Haemostasis in Patients With Postpartum Hemorrhage
|
N/A | |
Completed |
NCT02163616 -
Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study
|
Phase 3 | |
Not yet recruiting |
NCT02319707 -
Management of the Third Stage of Labor
|
Phase 3 | |
Recruiting |
NCT01600612 -
Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial
|
N/A | |
Completed |
NCT02079558 -
Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section
|
Phase 2 | |
Withdrawn |
NCT01108302 -
Effectiveness, Safety and Feasibility of Auxiliary Nurse Midwives' (ANM) Use of Oxytocin in Uniject™ to Prevent Postpartum Hemorrhage in India
|
N/A | |
Completed |
NCT00097123 -
RCT of Misoprostol for Postpartum Hemorrhage in India
|
N/A | |
Completed |
NCT02883673 -
Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage
|
N/A | |
Completed |
NCT02542813 -
Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers
|
Phase 1 | |
Completed |
NCT04201665 -
EMG for Uterotonic Efficiency Estimation
|
N/A | |
Terminated |
NCT03246919 -
Ideal Time of Oxytocin Infusion During Cesarean Section
|
Phase 4 | |
Not yet recruiting |
NCT05501106 -
Reducing Postpartum Hemorrhage After Vaginal Delivery
|
N/A | |
Completed |
NCT05429580 -
Prophylactic Tranexamic Acid Use After Vaginal Delivery
|
N/A | |
Terminated |
NCT03064152 -
Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery
|
N/A | |
Recruiting |
NCT05382403 -
Novel Vacuum-Induced Hemorrhage Control for Postpartum Hemorrhage
|
N/A | |
Not yet recruiting |
NCT02853552 -
Misoprostol as First Aid Measure to Address Excessive Postpartum Bleeding
|
Phase 4 | |
Completed |
NCT02910310 -
Introduction of UBT for PPH Management in Three Countries
|
N/A | |
Completed |
NCT02805426 -
Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage
|
Phase 4 |